Therefore, similar to β-thalassemia, genome editing therapies for SCD include not only HBB mutant gene correction via HDR but also gene disruption of BCL11A or HBG1/2 promoters to reactivate HBG expression via NHEJ (90, 96) (Table 2). This evidence concerns the gene HBG1 and Schnyder corneal dystrophy.